Ahead of long-term outcomes data from its cardiovascular outcomes study of Vascepa in September, Amarin Corporation plc (NASDAQ:AMRN) shares increased by 23.9% in August, according to S&P Global Market Intelligence.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,